GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (FRA:TN70) » Definitions » Cyclically Adjusted PB Ratio

Titan Pharmaceuticals (FRA:TN70) Cyclically Adjusted PB Ratio : 0.01 (As of Jun. 10, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Titan Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-06-10), Titan Pharmaceuticals's current share price is €5.917. Titan Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €547.48. Titan Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.01.

The historical rank and industry rank for Titan Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:TN70' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 2.36   Max: 286.4
Current: 0.01

During the past years, Titan Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 286.40. The lowest was 0.01. And the median was 2.36.

FRA:TN70's Cyclically Adjusted PB Ratio is ranked better than
99.85% of 661 companies
in the Biotechnology industry
Industry Median: 1.67 vs FRA:TN70: 0.01

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Titan Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was €6.124. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €547.48 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Titan Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Titan Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Titan Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.02 0.01

Titan Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.01 0.01 0.01

Competitive Comparison of Titan Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Titan Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Titan Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Titan Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Titan Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Titan Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=5.917/547.48
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Titan Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Titan Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=6.124/131.7762*131.7762
=6.124

Current CPI (Mar. 2024) = 131.7762.

Titan Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 567.706 100.560 743.939
201409 593.345 100.428 778.557
201412 1,256.115 99.070 1,670.804
201503 695.153 99.621 919.530
201506 317.774 100.684 415.906
201509 1,426.391 100.392 1,872.314
201512 1,152.065 99.792 1,521.306
201603 882.765 100.470 1,157.828
201606 2,671.477 101.688 3,461.930
201609 2,308.659 101.861 2,986.681
201612 2,123.090 101.863 2,746.567
201703 1,683.871 102.862 2,157.198
201706 1,139.049 103.349 1,452.355
201709 575.212 104.136 727.890
201712 122.920 104.011 155.733
201803 -116.469 105.290 -145.768
201806 -190.832 106.317 -236.530
201809 429.982 106.507 531.998
201812 276.937 105.998 344.287
201903 120.930 107.251 148.584
201906 -21.245 108.070 -25.905
201909 -84.677 108.329 -103.004
201912 13.489 108.420 16.395
202003 30.652 108.902 37.090
202006 8.547 108.767 10.355
202009 -3.916 109.815 -4.699
202012 8.133 109.897 9.752
202103 16.997 111.754 20.042
202106 14.720 114.631 16.922
202109 12.919 115.734 14.710
202112 9.173 117.630 10.276
202203 11.889 121.301 12.916
202206 7.329 125.017 7.725
202209 4.903 125.227 5.159
202212 1.714 125.222 1.804
202303 -0.388 127.348 -0.401
202306 -1.271 128.729 -1.301
202309 10.149 129.860 10.299
202312 7.793 129.419 7.935
202403 6.124 131.776 6.124

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Titan Pharmaceuticals  (FRA:TN70) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Titan Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Titan Pharmaceuticals (FRA:TN70) Business Description

Traded in Other Exchanges
Address
400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

Titan Pharmaceuticals (FRA:TN70) Headlines

No Headlines